Content Conference Coverage Conferences AIDS 2016
AIDS 2016: Efavirenz Appears Associated with Elevated Suicide Risk in START Trial
- Details
- Category: HIV Treatment
- Created on Thursday, 04 August 2016 00:00
Participants in the START treatment-timing trial who took antiretroviral regimens containing efavirenz had an increased risk of suicidal and self-injuring behavior than those not using efavirenz, though the number of events was small and the effect was mainly seen among people with a prior psychiatric diagnosis, according to research presented at the 21st International AIDS Conference last month in Durban.
Coverage of 21st International AIDS Conference (AIDS 2016)
- Details
- Category: HIV Treatment
- Created on Thursday, 28 July 2016 00:00
HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.
Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.
7/28/16
AIDS 2016: Starting Treatment on the Day of HIV Diagnosis Improves Outcomes
- Details
- Category: HIV Treatment
- Created on Thursday, 28 July 2016 00:00
Interventions to improve linkage to HIV care and retention in treatment which speed up the start of antiretroviral therapy (ART) or provide intensive support to people before starting treatment produce better retention than standard practices, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban.
AIDS 2016: START Analysis Looks at Who Benefits Most from Immediate HIV Treatment
- Details
- Category: HIV Treatment
- Created on Thursday, 28 July 2016 00:00
Starting antiretroviral therapy (ART) soon after HIV diagnosis led to better outcomes than delayed treatment in all population subgroups in the START trial, researchers reported at the 21st International AIDS Conference (AIDS 2016) last week in Durban. But some people saw greater risk reductions, including those over age 50, those with a lower CD4:CD8 ratio and higher viral load, and those with cardiovascular risk factors.
AIDS 2016: Early HIV Treatment -- Mothers Say They Need Time to Think
- Details
- Category: HIV Treatment
- Created on Thursday, 28 July 2016 00:00
Findings from the first randomized controlled trial to date evaluating postpartum antiretroviral therapy (ART) for women with high CD4 cell counts (over 400 cells/mm3) highlight a critical need to increase treatment acceptance in this population, according to research presented at the 21st International AIDS Conference (AIDS 2016) last week in Durban.
More Articles...
- AIDS 2016: Once-Daily Raltegravir Works as Well as Twice-Daily For Initial HIV Treatment
- AIDS 2016: Dolutegravir Plus Lamivudine Works Well as First-Line HIV Treatment
- AIDS 2016: Gains in Curbing HIV Could Be Lost Without Continued Commitment
- AIDS 2016: International AIDS Conference Starts Next Week in Durban
- AIDS 2016: International AIDS Conference Coming Up in Durban
- AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy
- AIDS 2016: Realism Needed About the Benefits and Risks of Taking Part in HIV Cure Research
- AIDS 2016: HIV Will Only Be Cured with Combined Approaches, Conference Delegates Hear
- AIDS 2016: International AIDS Society Releases New HIV Cure Research Strategy
- AIDS 2016: Seeking a Cure, Doctors Document Bone Marrow Transplant Recipients with HIV
- AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function
- AIDS 2016: Mapping Local HIV Epidemics Can Help Target Resources to Areas with Greatest Need
- AIDS 2016: HIV Viral Load Pilot Study Shows Roll-Out Will Depend on an Educated Workforce
- AIDS 2016: How Can Clinical Services Engage Men Who Have Sex With Men in Africa?
- AIDS 2016: NYC Clinic Outlines How to Improve PrEP Uptake by Transgender People
- AIDS 2016: Vaginal Ring for HIV Prevention is Effective and Acceptable
- AIDS 2016: Vaginal Bacteria May Increase HIV Susceptibility and Reduce PrEP Effectiveness
- AIDS 2016: Large Test-and-Treat Study Fails to Show Impact on New HIV Infections
- AIDS 2016: More Confidence on Zero Risk -- Still No Linked HIV Infections in PARTNER Study
- AIDS 2016: SEARCH Study Exceeds 90-90-90 Targets After 2 Years of HIV Test-and-Treat
- AIDS 2016: PrEP Study Achieves High Engagement and Adherence Among Black Gay Men
- AIDS 2016: Study Looks at Use of HIV PrEP Before and During Pregnancy and Breastfeeding
- AIDS 2016: No New HIV Infections Seen in San Francisco's Strut PrEP Program
- AIDS 2016: PrEP Rollout in France Tops 1000, Ipergay Shows 97% Effectiveness
- AIDS 2016: Bone Loss Recovers After Stopping PrEP, Biannual Kidney Monitoring Enough for Most
- AIDS 2016: Study Looks at Comprehensive HIV Treatment and Prevention Services for Sex Workers
- AIDS 2016: Progress Towards 90-90-90 Targets in Southern Africa -- Find the Men!
- AIDS 2016: Australia Adopts Ambitious Plan to Use PrEP to "Virtually Eliminate" HIV
- AIDS 2016: Young Gay Men Can Do Well on PrEP, But May Need More Support
- AIDS 2016: PrEP Can Further Reduce HIV Risk After Partner Starts Antiretroviral Treatment
- AIDS 2016: PrEP Use Exceeds 79,000 in U.S., But Some Groups Lagging Behind
- AIDS 2016: Researchers Now Focusing on Best Ways to Get PrEP to People Who Need It
- AIDS 2016: New HIV Vaccine Efficacy Trial Set to Start this Year
- AIDS 2016: Market Constraints and Uncertainties May Limit Scale-Up of HIV Self-Testing
- AIDS 2016: Access to Home Testing Doubles Frequency of HIV Testing Among Australian Gay Men
- AIDS 2016: Neglect of Infectious Disease in Prisons Highlighted at Conference
- AIDS 2016: New HIV Infections Have Stopped Declining Worldwide, Now Rising in Some Regions
- AIDS 2016: South Africa Has Driven Mother-to-Child HIV Transmission Down to 4%
- AIDS 2016: New Strategy Aims to End AIDS in Children by 2020
- AIDS 2016: HIV Treatment Programs Need to Prepare for a "Youth Bulge"
- AIDS 2016: San Francisco Sees Progress in Getting to Zero Initiative
- AIDS 2016: Progress Towards 90-90-90 Targets is Promising, But Funding Is the Critical Step
- AIDS 2016: Second Durban Declaration Highlights Key Advances and Barriers
- AIDS 2016: Earlier HIV Treatment Is Not Over-burdening Health Services
- AIDS 2016: Infection Prophylaxis Reduces Risk of Death for People Starting HIV Treatment Late
- AIDS 2016: Reducing Clinic Visits Supports Retention in HIV Care, African Studies Show
- AIDS 2016: HIV Criminalization on the Rise, Especially in Sub-Saharan Africa
- AIDS 2016: HIV Stigma Persists in the Undetectable Era
- AIDS 2016: Ongoing Hepatitis B Virus Replication Raises Mortality for People with HIV
- AIDS 2016: AbbVie 3D and 2D Hepatitis C Combos Work Well for HIV/HCV Coinfected People
- AIDS 2016: Sofosbuvir/ Velpatasvir Shows High Cure Rate in HIV/HCV Coinfection Study
- AIDS 2016: New WHO Algorithm Aims to Prevent TB Deaths in People with Advanced HIV
- AIDS 2016: High-Dose Rifampicin for TB May Improve Survival of HIV+ People with Low CD4 Counts
- AIDS 2016: Does Detectable CMV Signal High Mortality Risk for Older People with HIV and TB?
- AIDS 2016: Training Community Health Workers Leads to Surge in TB Diagnoses in Malawi
- AIDS 2016: TB 2016 Demands a Global Commitment to End Tuberculosis
- AIDS 2016: Shortened Regimen for MDR-TB Shows Good Results for Children
Web Design and Development by